A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

ConditionEssential Hypertension

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age19+

SponsorAddpharma Inc.

About this trial

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent

Patients with Essential Hypertension

Other inclusions applied

Disqualifiers

Patient with Secondary Hypertension

Other exclusions applied

Trial design

Design model

Parallel

Treatments tested in this trial

AD-227A
Drug
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227B
Drug
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227C
Drug
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227B
Drug
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227C
Drug
Per Oral, 1 Tablet, Once a day for 8 weeks

Treatment groups

251 Participants

are divided into 3 treatment groups

Group A: Co-administration of AD-227A and AD-227BExperimental treatment 3 interventions

Group B: AD-227AActive comparator 3 interventions

Group C: Co-administration of AD-227A and AD-227CActive comparator 3 interventions

Trial outcomes

Primary outcomes

Change in MSSBP

Change from Baseline in Mean Sitting Systolic Blood Pressure

Time frame

Baseline to Week8

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

Apply now